Additionally, a one SD increase in the expression of the DPP4 gene in the blood increased the incidence of COPD by 18% (OR = 1.18, 95% CI = 1.03–1.35; P = 0.022), implying that HMGCR agonists and DPP4 inhibitors may reduce the risk of COPD. The gene discussed is HMGCR; the disease is chronic obstructive pulmonary disease.